Some of appropriate 7-alkyl-8-piperazine derivatives of 3-methylxanthine were tested for their effect oncirculatory system, protection against adrenaline-, strophanthin-, and calcium chloride-induced arrhythmias, as wellascatecholamine metabolism in the heart of experimental animals. The most prominent antiarrhythmicactivity in this row was demonstrated by7-isopropyl-8-piperazine-3-methylxanthine (compound 3) that in a conditional therapeutic dose of 13.7mg/kg prevented or decreased the incidence of adrenaline, strophanthine and calcium chloride evoked arrhythmias. In adrenaline and calcium-evoked model of arrhythmia compound 3decreased or delayed the incidence of arrhythmias by 37% and 55.7% respectively, as well as episodes and severity of extrasystoles by 37%, efficiently prevented bigeminy (70%, p < 0.01) and diminished (42.8%, p<0.05) mortality of animals. Some of investigated compounds (2-5) decreased heart rate by 10-18%, prolonged P-Q section, QRS complex and Q-T interval.
Introduction
Despite huge improvements in cardiovascular care in the past 30 years and the decline in cardiovascular deaths over the past several decades due to improved preventative strategies, the incidence of sudden cardiac death (SCD) as a proportion of overall cardiovascular deaths has increased. SCD and arrhythmia continues to represent a major international public health problem and is still the biggest killer worldwide, accounting for 17 million deaths every year with sudden cardiac death accounting for 25 % of these [7] . Medical therapy with class IC agents or amiodarone to prevent SCD has been shown to be to be ineffective [4] . Methylxanthines of natural and synthetic origin are of biological and pharmacological interest. Independence on the kind and place of substitution none of the methylxanthine rings, a large variety of pharmacological activities have been reported [2, 5, 6] . Early repolarization has been associated with an increased risk of sudden cardiac arrest. Interestingly, ventricular arrhythmias seem to be triggered by parasympathetic stimulation. The theophylline mediated enhanced betaadrenergic stimulation could reduce the transmural myocardial voltage discrepancy by increasing the inward ICa,L current [1, 3, 9] .
The aim of the study: to investigate antiarrhythmic activity of some newly synthesized derivatives of 7-alkyl-8-piperazine-3-methylxanthine [compounds [1] [2] [3] [4] [5] [6] [7] and possible mechanisms of their antiarrhythmic action in the models of arrhythmias.
Design and Methods
The studies were carried out on mature white nonlinear male rats weighing 180-200 g collected from the breeding center of Institute of Pharmacology and Toxicology of the Academy of Medical Sciences of Ukraine. The control and study groups consisted of 7animalseach. The animals were kept in plastic cages on a standard food ration and free access to water in a room temperature of 20 ± 4 ºC in natural alternation of day and night. Treatment of the used laboratory animals in the present study was in full accordance with Commission on Bioethics and Pharmacy "General ethical animal experimentation" (8) , consistent with the provisions of the European Convention "On protection of vertebrate animals used for experimental or other scientific purposes" undersigned in Strasbourgin1986 [8] . Some newly synthesized derivatives of 7-alkyl-8-piperazine-3-methylxanthine were object of the research (compounds 1-7, Table 1 ). The determination of antiarrhythmic activity of agents was carried out using an intravenous injection. The agents under investigation were preliminary dissolved in physiological salt solution with the addition of Twin 80; the obtained injection form was injected into a femoralvein of an animal through a catheter at dozevalues specified in Table 1 .Arrhythmiaswere evoked in rats anesthetized with sodium thiopental(40mg/kg, ip) by a single iv injection into the same vein of adrenaline at a dose of 0.3mg/kg, strophanthin0.4mg/kg orcalcium chloride 250mg/kgin a volume of 1 mL/kg. Such adrenaline, strophanthinandCaCl2dozes were lethal ones in 100 % of cases. We used two protocols in the experiments: the studied compounds were injected either 1 minprior to the injection of an arrhythmogen or10 sec after the injection. As reference drugs applied in medical practice as antiarrhythmic agents, Procainamide and Ajmaline were injected once intravenously at a dose of 20 mg/kg and 2 mg/kg respectively. Electrocardiographic studies were carried out on anesthetized rats onEEGP4-02apparatus.The electrocardiogram was registered using second standard (bipolar extremity) lead at a tape speed of 50 mm/s within10 min. The frequency of supraventricular (atrial fibrillation, supraventricular paroxysmal tachycardia) and ventricular (ventricular extrasystoles, ventricular tachycardia, ventricular fibrillation) arrhythmias were calculated in each group. Evaluation of antiarrhythmic properties of studied compounds was made according to the following criteria: frequency and severity of arrhythmias on the background of application of investigated compounds, ability of the compound to delay the beginning of arrhythmias, the life expectancy of animals, and the survival time of animals in control and studied group. Attenuation or the lack of disturbances and the decreased mortality after adrenaline-, strophanthin-, and calcium chloride-induced arrhythmias against a background of investigated compounds action were accepted as a criterion of their antiarrhythmic effect in comparison with the control group. Since СаСl2and adrenaline arrhythmias are primarily of adrenergic nature, the contents of adrenaline, noradrenaline, 3,4-dioxyphenylalanine and dopamine were investigated in the myocardium of experimental animals before and after application of the investigated compounds. After decapitation the myocardium was removed from the thorax and placed in the liquid nitrogen. Then it was crushed on the ice, and homogenate was prepared to calculate the catecholamines levels [3] . The contents of catecholamines were evaluated by the spectrofluorometricmethod on the fluorimeter F-3 connected with stabilizer BC-9. The results of the study have been processed with application of Statistical Software Package «STATISTICA ® for Windows 6.0» (StatSoft Inc., № AXXR712D833214FAN5), as well as «SPSS 16.0», «Microsoft Excel 2003».
A mean error value was taken as average deviation; the results were processed using Student's t test. The results for all forms of analysis were statistically significant at a significance level of p<0.05.
Results and Their Discussion
The analysis of the obtained results on the strophanthine model of arrhythmias showed that some of 7-isopropyl-8-piperazine-3-methylxanthinederivatives possess antiarrhythmic properties ( Table 2 ). After strophanthine injection arrhythmias developed after latent period of 137±18 sec. Supraventricular and ventricular arrhythmias developed (83%), disturbances of atrioventricular conductance, ventricular arrhythmias (77.8%) and atrial fibrillation (22%). There was bradycardia and insignificant atrial conduction disorder observed in the beginning indicated by the reduction of P wave amplitude. It was also established that there was anincrease of R wave amplitude observed that appeared in 1.2 min and disappeared in several minutes. The most prominent antiarrhythmic activity was demonstrated by 7-isopropyl-8-piperazine-3-methylxanthine (compound 3) that has isopropyl substitute in the 7 th position. Its substitution by γ-chlorbutenyl-2 (compound 1) or hydroxyethyl (compound 7) led to a decrease in antiarrhythmic activity. In a conditional therapeutic dose of 13.7 mg/kg compound 3 decreased the incidence of strophanthine evoked arrhythmias by 71.4% as well as episodes and severity of extrasystoles (by 37%), efficiently prevented bigeminy (71.4%, p < 0.01) and diminished (50%, p < 0.05) mortality among animals. As adrenaline arrhythmia developed, there were bradycardia and insignificant atrial conduction disorder observed indicated by the reduction of P wave amplitude. Further a recovery occurred, both of cardiac beat frequency and of P wave amplitudes. In the case of lethal termination, the ventricular premature beats arose against a background of acute bradycardia with an atrioventricular heart block of various degrees, which in 2.3 min passed into a polytopic extrasystoles and ventriculartachycardia. The bradycardia was of reflexnature as a response to an abrupt increase in arterial pressure caused by adrenaline. Preliminary introduction of compounds 3 and 6 containing in the 7 th position isopropyl and 2-cyclopentyl substituents respectively prevented development of adrenaline arrhythmias totally. Under the development of calcium chloridearrhythmia in the case of a lethal termination there was an atrial flutter observed passing into atrial conduction disorder aswell as into a sinoatrial node block (Table 3) . Then atrioventricularbradycardia occurred with a subsequent development of severe ventriculartachycardia and cardiac arrest. Analysis of obtained results showed that all investigated compounds prevented the development of CaCl2 evoked arrhythmias. Compound 3 was given iv10 sec after the arrhythmogen. It was found to induce a gradual disappear once of the arrhythmia and restoration of the sinus rhythmin comparison with the control group in the models of adrenaline andCaCl2 arrhythmias as well as to attenuate the severity of strophanthine arrhythmias. It was found that compound 3 in a conditionally therapeutic dose of 13.7 mg/kg had decreased the severity of arrhythmias, prolonged mean latency period (i.e. the interval between injection and appearance of the first extrasystoles), reduced the duration of arrhythmia, and decreased the percentage of mortality in experimental animals. In a separate series of experiments, performed on intact animals anaesthetized by sodium thiopental we investigated the effect of compounds 3and 5 on electrophysiological processes in myocardium. There were no statistically significant differences within 30 min after the injection of the studied compound at a dose of 13.7 mg/kg in bioelectrical activity of the myocardium. The survival rate of animals was 85% on the model of strophanthine arrhythmias, 100% in CaCl2 and 85% in adrenaline evoked arrhythmias respectively. Thus, compound 3 has been uncovered to have not only antiarrhythmic properties, but the cardioprotective effect in the models of strophanthine, adrenaline and CaCl2 evoked arrhythmias. Arrhythmias either did not occur, or occurred much later; and they were less severe and threatening to the life against the background of the compound. The study of the catecholamines and their precursors levels in the myocardium of intact rats as well as in rats after the development of CaCl2 evoked arrhythmias detected increasing levels of epinephrine by 65.5%,and norepinephrineby 106.8% as well as reduction in dopamine level by 48.2% after the arrhythmogen introduction ( p<0.01). DOPA levels (0.218±0.015) did not have any statistically significant differences (р>0.05) (table 4). Arrhythmias are a result of changes to the basic functions of the heart: automatism, excitability and conductivity. They are developing due to the disturbances of the potential action formation as well as changes in the speed of its conduction as a result of abnormal functioning of K + , Na + , and Ca 2+ channels. Abnormal activity of K + , Na + , and Ca 2+ channels depend on sympathetic activity, acetylcholine levels, cholinergic M2-receptors, ATP.
All investigated compounds decreased heart rate by 12 to 18%, prolonged P-Q section, QRS complex and Q-T interval. The most potent and significant negative chronotropic effect and markedly prolonged duration of P-Q section was demonstrated by compound 3. The influence of investigated compounds on ECG characteristics suggests that activity of compound 3 is similar to class 1A antiarrhythmic drugs according to Voughan-Williams classification of antiarrhythmic agents, because of prolongation of P-Q and Q-T intervals and extension of QRS complex. It has been established that its antiarrhythmic activity exceeds reference preparations novocainamide and aimaline on the models of adrenaline, strophanthine and calcium chloride arrhythmias confirming that the compound possesses the properties of class 1A antiarrhythmics and has a wide therapeutic window. It has been established that its antiarrhythmic activity exceeds reference preparations procainamide and ajmaline on the models of adrenaline, strophanthine and calcium chloride arrhythmias indicating that the compound possesses properties of class 1A antiarrhythmics and has a wide therapeutic window. The mechanism of the antiarrhythmic of action of compound 3 includes not only blockade of Na + channels of the conducting system of the heart, consequent indirect suppression of K + exit from the cell and blockade of intracellular Ca 2+ depot, but also normalization of heart tissue catecholamine and their precursor content, along with the interference in the activity of the enzyme systems participating in the biotransformation of catecholamines. Analyzing the antiarrhythmic activity of the studied compound it should be noted the participation of several mechanisms in the implementation of its effects. It is known that arrhythmias evoked be by CaCl2, cardiac glycosides and adrenaline have common mechanisms in increasing the inward Са 2 + flow through the slow Ltype Са 2 + channels in the cell and increase in its concentration leads to increase of excitability of the myocardium [1, 3] . Therefore, we can assume that the antiarrhythmic effect develops either due to the restriction of inwardСа 2 + flow through the slow L-type Са 2 + channels in the cell, or the increase in the effectiveness of Са 2+ pumps that removeexcessiveСа 2 + from cytoplasm. Thus, there is every reason to believe that the mechanism of action of compound 3 is complex and is caused by not only antagonistic interaction with calcium ions but normalization of content of epinephrine, norepinephrine, dopamine, as a result of interference in the activity of the enzyme systems that are involved in catecholamine metabolism. In addition, the activity of the compound 3 in adrenaline evoked arrhythmia seems to be caused by a reduction of adrenergic response of the myocardium. However, blockers of ß-adrenergic receptors as well as inhibitors of Са 2 + -channels have negative inotropic action. It should be noted the preservation of inotropic functions of myocardium against the background of the introduction of compounds 3 and absence of any negative inotropic action after its administration against along with significant antiarrhythmic activity. Thus, the most likely mechanism of antiarrhythmic action of compounds 3 should recognize the inhibition of Na + /Са 2+ exchange, decreased calcium ion inward and/or increase in the efficiency of the calcium pump.
Conclusions
1. The results of the study have exhibited that some derivatives of 7-alkyl-8-piperazine-3-methylxanthine had antiarrhythmic properties, produced antifibrillatory and cardioprotective effects, and increase electrical stability in the myocardium. 2. Based on the in vivo experiments it seems that 7-isopropyl-8-piperazine-3-methylxanthine (3) is the most promising compound that caused the significant antiarrhythmic protection at a dose of 13.7 mg/kg within 0.5 h after iv administration in rat models of adrenaline, strophanthine and calcium chloride-evoked arrhythmias. 3. The mechanism of antiarrhythmic action of compound 3 is caused by not only inhibition oninwardCa 2+ flow, but also regulation of catecholamines and their precursors levels in the myocardium, and interference in the activity of enzyme systems involved in the metabolism of catecholamines. 4. The obtained preliminary in vivo results encourage further search in the group of 3-methylxanthines as the agents possessing antiarrhythmic activity.
